In silico study of the active compounds in bitter melon (Momordica charantia L) as antidiabetic medication

Authors

  • Ruswanto Ruswanto Prodi Farmasi, STIKes Bakti Tunas Husada Tasikmalaya
  • Richa Mardianingrum Department of Pharmacy, Perjuangan University, Tasikmalaya
  • Tresna Lestari Prodi Farmasi, STIKes Bakti Tunas Husada Tasikmalaya
  • Tita Nofianti Prodi Farmasi, STIKes Bakti Tunas Husada Tasikmalaya
  • Lilis Tuslinah Prodi Farmasi, STIKes Bakti Tunas Husada Tasikmalaya
  • Dudi Nurmalik Prodi Farmasi, STIKes Bakti Tunas Husada Tasikmalaya

DOI:

https://doi.org/10.12928/pharmaciana.v8i2.8993

Keywords:

Momordica charantia L, Goyaglikosida-h, Antidiabetic, in silico

Abstract

Antidiabetic are many drugs available in the market, but most medications have side effects that are relatively high and cause toxicity, so it needs tobe develoved search of new drug compounds were more potent drugs with side effects as low. Various research have shown that bitter melon (Momordica charantia L) has an effect antidiabetic. But it is not known specifically as antidiabetic compounds that act on bitter melon (Momordica charantia L). This study was conducted to predict the active compounds of bitter melon (Momordica charantia L)potent as antidiabetic in silico, through the molecular docking, Drug scan, PreADMET and molecular dinamics simulation. The results of the 26 active compound bitter melon (Momordica charantia L) obtained one potential compounds that are active against nuclear reseptor RORα that is goyaglikosida-h and more potent than Rosiglitazon

References

Departemen Kesehatan RI., 1995, Materia Medika Indonesia, Jilid VI, Jakarta: Direktorat Jendral Pengawasan Obat dan Makanan.

Farkhani Aulia, 2012, Analisis Dinamika Molekuler Hasil Penambatan Kompleks α-Glukosidase Dengan Sulokrin [Skripsi], Depok: FMIPA Universitas Indonesia.

Fatimah RN., 2015, Diabetes melitus tipe 2 [Ulasan]. J Majority., 4(5): 93-101.

Gunawan SG, Setiabudy R, Nafrialdi, Elysabeth, 2011. Farmakologi dan Terapi. Edisi 5. Jakarta: Badan Penerbit FKUI.

Harganingtiyas R., 2011, Modifikasi (1R,2R,3R,5R)-(-)- isopinocampheylamine sebagai inhibitor M2 proton channel pada virus influenza A subtipe H1N1 secara In silico [Skripsi]., Jakarta: Universitas Indonesia.

Kementrian Kesehatan Republik Indonesia, 2014, Situasi dan analisis diabetes: Waspada diabetes Eat well live well, InfoDATIN: Pusat Data dan Informasi Kementerian Kesehatan RI. 1-7.

Kojetin DJ, Burris TP., 2014, REV-ERB and ROR nuclear receptors as drug targets, Nature Review: Drug Discovery, Vol. 13: 197-216.

Levita J, Mustarichie R., 2012, Pemodelan Molekul Dalam Kimia Medisinal, Yogyakarta: Graha Ilmu.

Mulyanti S, Musthapa I, Aisyah S., 2010, Isolasi dan karakterisasi senyawa metabolit sekunder dari fraksi aktif antidiabetes daging buah paria (Momordica charantia Linn), Jurnal Sains dan Teknologi Kimia, 1(2). 191-199.

Mutschler, E., 1999, Dinamika Obat: Farmakologi dan Toksikologi, Ed.5. Bandung: Penerbit ITB.

Nugroho AE., 2012, Farmakologi: Obat-Obat Penting dalam Pembelajaran Ilmu Farmasi dan Dunia Kesehatan, Yogyakarta: Pustaka Pelajar.

Nurbaiti S. 2009, Stabilitas Termal dan Pergerakan Dinamis Klenow-like DNA Polymerase I ITB-1 Berdasarkan Simulasi Dinamika Molekul, Disertasi: Program Studi Kimia-Institut Teknologi Bandung.

Pratiwi D, Insanu M, Damayanti S., 2014, Prediksi Toksisitas Senyawa Antioksidan Alami Dan Analisis Interaksinya Terhadap Reseptor Vegf-1 Menggunakan Metode Molecular Docking. Farmagazin, 1(1), 1-9.

Purnomo H., 2013, Kimia Komputasi Uji In Silico Senyawa Antikanker, Yogyakarta: Pustaka Pelajar.

Ruswanto, Richa, M., Tita, N., Tresna, L., 2017, Molecular Docking of 1-Benzoyl-3-Methylthiourea as Anti Cancer Candidate and Its Absorption , Distribution , and Toxicity Prediction 9, Journal of Pharmaceutical Sciences and Research, 9(5), 680–684.

Ruswanto, Mardianingrum, R., Novitriani, K., 2015. Sintesis Dan Studi in Silico Senyawa 3-Nitro-N’-[( Pyridin-4-Yl ) Carbonyl ] Benzohydrazide Sebagai Kandidat Antituberkulosis, Jurnal Chimica et Natura Acta, 3(2), 54-61.

Saleh W., 2015, Studi hubungan kuantitatif struktur-aktivitas anti-tuberkulosis senyawa amidasi etil p-metoksisinamat dengan pendekatan Hansch dan penambatan molekuler pada enzim Inh A. [Skripsi],Jakarta: Program Studi Farmasi Fakultas Kedokteran dan Ilmu Kesehatan UIN Syarif Hidayatullah.

Unadi YC,. 2013, Perancangan Pentapeptida Siklis Sebagai Inhibitor Neuroaminidase Virus H5N1 Melalui Docking Dan Simulasi Dinamika Molekul. [Tesis], Depok: FMIPA Universitas Indonesia.

Wulandari, Evi Kristin, 2010, Karya Pascasarjana Kimia: Analisis Interaksi Histone Deacetylase (HDAC) Kelas II Homo Sapiens Dengan Suberoyllanilide Hydroxamic Acids (SAHA) dan Trichostantin A (TSA). Depok: Departmen Kimia FMIPA UI.

Yuda IKA. Anthara MS, Dharmayuda A.A.G.O., 2013, Identifikasi golongan senyawa kimia ekstrak etanol buah pare (Momordica charantia L) dan pengaruhnya terhadap penurunan kadar glukosa darah tikus putih jantan (Rattus novergicus) yang diinduksi aloksan, Buletin Veteriner Udayana, Vol. 5(2).87-95

Downloads

Published

2018-11-24

Issue

Vol. 8 No. 2 (2018): Pharmaciana

Section

Analytical Pharmacy and Medicinal Chemistry

License

Authors who publish with Pharmaciana agree to the following terms:

  1. Authors retain copyright and grant the journal the right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC BY-SA 4.0) that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal. 
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.